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Understanding how to achieve efﬁcient transduction of hematopoietic stem and progenitor cells (HSPCs), while
preserving their long-term ability to self-reproduce, is key for applying lentiviral-based gene engineering
methods. SAMHD1 is an HIV-1 restriction factor in myeloid and resting CD4+ T cells that interferes with reverse
transcription by decreasing the nucleotide pools or by its RNase activity. Here we show that SAMHD1 is
expressed at high levels in HSPCs cultured in a medium enriched with cytokines. Thus, we hypothesized that
degrading SAMHD1 in HSPCs would result in more efﬁcient lentiviral transduction rates. We used viral like
particles (VLPs) containing Vpx, shRNA against SAMHD1, or provided an excess of dNTPs or dNs to study this
question. Regardless of the method applied, we saw no increase in the lentiviral transduction rate. The result
was different when we used viruses (HR-GFP-Vpx+) which carry Vpx and encode GFP. These viruses allow as-
sessment of the effects of Vpx speciﬁcally in the transduced cells. Using HR-GFP-Vpx+ viruses, we observed a
modest but signiﬁcant increase in the transduction efﬁciency. These data suggest that SAMHD1 has some limited
efﬁcacy in blocking reverse transcription but the major barrier for efﬁcient lentiviral transduction occurs before
reverse transcription.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gene engineered hematopoietic stem and progenitor cells (HSPCs)
are the basis of a promising therapeutic approach for a variety of dis-
eases, including HIV/AIDS, Wiskott–Aldrich syndrome and metachro-
matic leukodystrophy (Cartier & Aubourg, 2010; Sheridan, 2011; Aiuti
et al., 2013; meBifﬁ et al., 2013). Gene engineering has become more
feasible since retroviruses were found to integrate into the host chro-
mosome and retroviral vectors were developed (Sheridan, 2011).
Gene engineering of HSPCs seems straightforward, but challenging
technical issues remain, including efﬁcient transduction of HSPCs with-
out disrupting their multi-potency, ex vivo or in vivo selection of gene
engineered cells, generation of sufﬁcient numbers of gene engineered
cells and ultimately homing and efﬁcient engraftment (Millington et al.,
2009; Glimm et al., 2000; Barquinero et al., 2000). Transduction is most
efﬁcient when cells are activated and dividing. In that case, HSPCs will
differentiate and lose their multi-potency. Unlike retroviral vectors,
lentiviral vectors beneﬁt from HIV's capacity to enter the nucleus of
non-dividing cells, while using the envelope of unrelated viruses to
widen their tropism (Frimpong & Spector, 2000; Cronin et al., 2005). Al-
though lentiviral vectors eliminate the strict requirement for cell division,
they still need HSPCs to be stimulated to progress into the late G1 phase
for efﬁcient transduction (Miller et al., 1990). Thus, despite many efforts
to achieve higher transduction rates for HSPCs, the lentiviral transduction
efﬁciency is still low (20–30%) when avoiding harsh activation and pro-
liferation, and this is a major limitation for efﬁcient gene engineering.
In addition, multiple integration events may result in disruption of cell
homeostasis, and so, achieving single integration events is a signiﬁcant
goal.
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The sterile alpha motif (SAM) domain and HD domain-containing
protein 1 (SAMHD1) were identiﬁed as a potent restriction factor for
HIV (Hrecka et al., 2011; Laguette et al., 2011). Its deoxyguanosine-
triphosphate (dGTP)-dependent triphosphate triphosphohydrolase ac-
tivity hydrolyses the deoxynucleoside triphosphates (dNTPs) to
deoxynucleoside (dNs) and inorganic triphosphate (Lahouassa et al.,
2012). SAMHD1 was originally proposed to limit HIV-1 infection by
depleting the intracellular levels of dNTPs to below those required for re-
verse transcription. Very recent data challenge this proposedmechanism
and present SAMHD1's RNase activity as crucial for HIV restriction (Ryoo
et al., 2014). Thismechanism appears to be plausible since the phosphor-
ylated form of SAMHD1 is unable to block HIV-1 infection, but still ac-
tively depletes the intracellular dNTP pools (White et al., 2013).
SAMHD1 is expressed in cells of the myeloid lineage, such as den-
dritic cells (DCs), monocytes and macrophages, as well as CD4+ T
cells, although SAMHD1 expression was reported as missing in T
cell lines (Hrecka et al., 2011; Laguette et al., 2011; Descours et al.,
2012; Baldauf et al., 2012). Moreover, the accessory viral protein
Vpx, which is encoded by HIV-2 and SIV variants, but not HIV-1, tar-
gets SAMHD1 for proteasomal degradation in myeloid and resting
CD4+ T cells. Therefore, Vpx facilitates HIV-1 reverse transcription
(Hrecka et al., 2011; Laguette et al., 2011). These ﬁndings strongly
implicate SAMHD1 as a key restriction factor that inhibits HIV-1 rep-
lication in myeloid cells and resting CD4+ T cells at the level of re-
verse transcription.
We hypothesized that SAMHD1 acts to restrict HIV-1-based
lentiviral HSPC transduction. To address this hypothesis, we assessed
the efﬁciency of lentiviral transduction of HSPCs under the following
conditions: 1) Vpx-mediated degradation of SAMHD1, 2) shRNA against
SAMHD1, 3) an excess of dNTPs or dNs, and 4) HR-GFP-Vpx+/−
lentivirus, which carries Vpx and encodes GFP.
2. Material and methods
2.1. Ethics statement
The use of human cord blood was approved by the ethical commit-
tee of the University of Zurich. Written informed consent was obtained
from the parents before collection.
2.2. Cells and reagents
Human peripheral blood mononuclear cells (PBMCs) were isolated
frombuffy coats, obtained from the local blood donation center in Zurich,
by Ficoll (Axis-Shield PoC AS, Oslo, Norway) gradient centrifugation.
Monocytes were puriﬁed using CD14 MicroBeads (Miltenyi Biotec,
Bergish Gladbach, Germany); the purity was N90%. Monocyte-derived
macrophages (MDMs) were generated as described (Schlaepfer et al.,
2014). HSPCs were isolated from human cord blood with immunomag-
netic beads (Miltenyi Biotec, Bergish Gladbach, Germany) with an yield
of 0.5–4 × 106 HSPCs from one donation (purity N 90%). HSPCs and
“non-target” fractions were stored frozen in liquid nitrogen until use.
THP-1, SupT-1, MT-2, U937 cells were cultured in RPMI 1640
(BioWhittaker) supplemented with 10% FBS, 1% glutamine (Invitrogen
Life Technologies), and antibiotics (Pen Strep). SAMHD1 shRNA, encoded
within a SIN vector cassette (St. Louis, MO, TRCN0000145408), and con-
trol mammalian non-target shRNA (SHC002) were purchased from
Sigma-Aldrich. THP-1 cells transduced with lentiviral vectors encoding
SAMHD1 shRNA were selected by culturing in a medium containing
0.8 μg/ml puromycin. dNs consisted of a mixture of dA (D8668), dC
(D0776), dG (D0901) and dT (T1895; all from Sigma-Aldrich). dNTPs
(R0192) were purchased from Fermentas (Glen Burnie, MD). Cytokine
cocktail for HSPC transduction consisted of a mixture of stem cell factor
(SCF) at 100 ng/ml, Fms-related tyrosine kinase 3 ligand (Flt3L) at
100 ng/ml, interleukin-3 (IL-3) at 60 ng/ml and thrombopoietin (TPO)
at 10 ng/ml (Immunotools, Friesoythe, Germany).
2.3. Viruses, and transduction procedure
Viruses were produced by transfection of 293T cells with
polyethylenimine (PEI) (Sigma-Aldrich) with the various constructs.
Mediawere replaced 16h post-transfection, and supernatantswere col-
lected and ﬁltered 48 h post-transfection; viruses were concentrated
100-fold with PEG-it™ (System Biosciences, Mountain View, CA). Len-
EF1α-GFP: To generate lentiviral particles encoding GFP, 293T
cells were co-transfected with the self-inactivating (SIN) vector pLen-
EF1α-GFP (kindly provided by D. Boden, Tibotec, Belgium),
pCMVΔR8.91 (containing the coding sequences for gag/pol, rev and
tat under the control of the CMV promoter) and pMD2.G (coding for
the vesicular-stomatitis virus (VSV-G) envelope) (both provided by D.
Trono, Switzerland). HR-GFP virus with Vpx incorporated: The HR-GFP
virus carrying Vpx was produced by co-transfection of the proviral
HIV-1 GFP plasmid HR-GFP, Vpx239+ (Vpx expression construct),
pR8.9NdeltaSB and pMD2.G; the Gag P6 in pR8.9NdeltaSB is modiﬁed
for better incorporation of Vpx (Baldauf et al., 2012). Vpx+ and Vpx−
viral like particles (VLPs) were produced by co-transfection with
pSIV3+ (Vpx+) or pSIV3+ Δvpx (Vpx−) (provided by A. Cimarelli,
Lyon) and pMD2.G in the absence of a viral genome. Lentiviruses con-
taining SAMHD1 shRNA and control mammalian non-target shRNA were
produced by co-transfection of lentiviral vectors which encode
SAMHDshRNA or control shRNAwith pCMVΔR8.91 and pMD2.G. All vi-
ruses encoding GFP were titrated on SupT-1 cells by measuring the fre-
quency of GFP+ cells by ﬂow cytometry (van Lent et al., 2010).
Transduction of HSPCswas done essentially as described (Amsellem
et al., 2002). Brieﬂy, HSPCs were resuspended in a HP01 medium
(Macopharma, Mouvaux, France) containing a mixture of cytokines
(see above). Three days later, transduction efﬁcacy was determined by
measuring the frequency of GFP+ cells by ﬂow cytometry.
2.4. Flow cytometry
HSPCs and monocytes were incubated with PBS containing 2% FBS,
2 mM EDTA (Invitrogen Life Technologies) and 0.1% sodium azide
(Sigma-Aldrich) for staining cell surface markers. Intracellular SAMHD1
(Abcam, Cambridge, UK) staining was performed as described (Baldauf
et al., 2012). Depending on the purpose of the experiment, the following
antibodies were used for staining HSPCs in various combinations: Lin-,
CD34, CD133, and CD38 (BD Biosciences, San Jose). Samples were ac-
quired on a CyAn™ ADP Analyzer (Beckman Coulter, Pasadena, CA) and
analyzed by FlowJo software (TreeStar, Ashland, OR). Gating strategy is
shown in Fig. 2A.
2.5. Quantitative PCR for measuring SAMHD1 mRNA
RNA from 2 × 106 of primary cells or cell lines was isolated using an
RNeasy kit (Qiagen, Hilden, Germany). Reverse transcription was
performed essentially as described (Audige et al., 2004). SAMHD1
mRNAwas quantiﬁed using commercially available primers and probes
(Assays-on-demand; Applied Biosystems, Foster City, CA) by real-time
quantitative PCR (RT-qPCR) analysis. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Applied Biosystems) was used as a house-
keeping gene. Data generated by RT-qPCR were analyzed as described
(Schlaepfer et al., 2014). For each sample, the mean normalized
gene expression (MNE) was determined with the software application
Q-Gene.
2.6. Western blot analysis
MDMs andHSPCswere pretreatedwith Vpx+/− viruses for 2 h and
cultured for 3 days before the preparation of whole-cell extracts. West-
ern blotting was performed essentially as described (Miller et al., 2011)
by using mouse anti-SAMHD1 (Abcam, Cambridge, UK), rabbit anti-
pSAMHD1 directed against the phosphorylated threonine (T592)
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(White et al., 2013), and rabbit anti-β actin (Cell Signalling, Danvers,
MA) antibodies in blocking buffer overnight at 4 °C. After three washes,
the membranes were incubated in HRP-conjugated anti-mouse or anti-
rabbit IgG secondary antibody (Cell Signalling) in a washing buffer for
1 h at room temperature. After three washes in a washing buffer, mem-
branes were incubated for 1 min with ECL detection reagents
(Amersham Biosciences, Little Chalfont, UK). Signals were quantiﬁed
with Adobe Photoshop CS3 software.
2.7. Quantiﬁcation of proviral DNA with Alu-PCR
Alu-PCR was performed with speciﬁc primers to human Alu se-
quences and to HIV-1-based lentiviral vector sequences as described
(Schlaepfer et al., 2014; Althaus et al., 2010). Results were considered
as valid only if the same results were obtained in at least three separate
experiments.
2.8. Quantiﬁcation of viral DNA intermediates
DNA was extracted from MDMs or HSPCs transduced with HR-
GFP-Vpx+ or HR-GFP-Vpx− lentiviruses with a QIAamp DNA Mini
kit (Qiagen) according to the manufacturer's instructions. Samples
treated with 1 μM efavirenz (EVF) or 30 μM raltegravir (RTV)
(EVF and RTV were provided by the NIH AIDS Reagent Program,
Germantown, MD), which block the reverse transcription and inte-
gration step, respectively, were used as negative controls. Real-
time PCR was performed by using primers and probes as described
(Butler et al., 2001). Reactions were carried out in 50 μl volumes con-
taining 400 ng of DNA in the presence of 600 nM of each primer and
80 nM of probes. Results were obtained from three independent ex-
periments using three donors.
2.9. Quantiﬁcation of whole cell dNTP pools
MDMs and HSPCs were exposed for 2 h to Vpx+/− viruses/dNs/
dNTPs and cultured for 3 days before the preparation of whole cell ex-
tracts. dNTPs were quantiﬁed as described (Diamond et al., 2004).
2.10. Immunoﬂuorescence
Adherent differentiated MDMs were exposed for 2 h to Vpx+/−
viruses, and infected with Len-EF1α-GFP lentiviral viruses for 6 h. At
day 5, MDMs were rinsed three times with phosphate-buffered sa-
line (PBS, Sigma-Aldrich). The adherent cells were ﬁxed in culture
plates with methanol at −20 °C (VWR International, Radnor, PA)
for 5 min and blocked with PBS plus 10% normal human serum
(Pel-Freez, Rogers, AR) for 20 min. Three rinses with PBS followed
all incubations, and all steps were performed at room temperature.
Fluorescence was detected as described (Kuster et al., 2000). In
every experiment, background FITC ﬂuorescence was determined
from identically processed uninfected cell lines and expressed as
total gray values (TGV) per cell. The FITC background was calculated
as [mean (log10 TGV) plus 3 SD] and then subtracted from measure-
ments on the MDMs. To deﬁne the total area of the cells, the nuclear
signal was measured with the DAPI ﬁlter.
2.11. Statistics
For statistical analysis, the statistical software GraphPad Prism
(Version 5) was used. The statistical test used for a given experiment
is indicated in the ﬁgure legends.
3. Results
3.1. SAMHD1 is highly expressed in HSPCs cultured in a medium enriched
with cytokines
We ﬁrst characterized HSPCs freshly isolated from cord blood by
staining for lineage markers and the cell surface markers CD34, CD133
and CD38 overtime. In one representative of three analyses (performed
with cells from three different donors), 87.2% of the cells were
CD34+Lin− and 84.3% of these cells were CD133+CD38+ (Fig. 1A).
Lin−CD34+CD133+CD38+ cells shifted partially after 12 h of cultiva-
tion to Lin−CD34+CD133−CD38+ cells, a process which continued
over the entire observation time. We observed also a loss of the Lin−
CD34+CD133+CD38− cells over time; The Lin−CD34+CD133+ cell
population correlates best with HSPC SCID repopulation capacity
(Drake et al., 2011).
SAMHD1 mRNA was expressed at much lower levels in freshly iso-
lated HSPCs than in HSPCs cultured for 3 days (Fig. 1B). SAMHD1 pro-
tein expression was already markedly increased at 2 h in culture and
progressively increased over the next 3 days (Fig. 1C and D). Notably,
retroviral restriction by SAMHD1 is regulated by its phosphorylation.
p-SAMHD1 is unable to block HIV-1 infection, but it still depletes intra-
cellular dNTP pools (White et al., 2013; Cribier et al., 2013). In the
present study, increased expression of SAMHD1 after 12 h of cell culture
did not lead to any concomitant increase of p-SAMHD1 expression
(Fig. 1E). Thus, we hypothesized that the increased levels of SAMHD1
when culturing HSPCs limit their susceptibility to transduction with
lentiviral vectors.
3.2. Transduction efﬁcacy of HSPCs with lentiviral vectors is not affected by
Vpx+ viruses, dNs or SAMHD1 shRNA pretreatment, and dNTPs only
marginally increase the transduction efﬁcacy of HSPCs
We optimized the transduction procedure for our purposes based
mainly on protocols previously reported in the literature (for details
see “Material and methods” section). HSPCs were challenged with SIN
vector pLen-EF1α-GFP-derived lentivirus at MOI of 100. The transduc-
tion efﬁciency was 30–50% as shown in Fig. 2A. Here, we explored
whether SAMHD1 affects the lentiviral-based transduction rate in
HSPCs.
We ﬁrst validated all the methods we used by documenting the Vpx-
mediateddegradation of SAMHD1 inMDMs and the subsequent increase
of transduction rates with lentiviral vectors. Experiments examining the
role of SAMHD1 in HSPCs were always done in parallel with MDMs as
positive controls. HSPCs were pretreated with either Vpx+/− viruses
from SIV for 2 h or were mock-treated and then transduced with Len-
EF1α-GFP-based viruses. Pretreatmentwith Vpx+viruses did not result
in a higher transduction rate than pretreatment with Vpx− viruses or
mock-treatment as determined by the number of GFP+ cells 3 days
post-transduction (Fig. 2B–D).
In previous work, the actions of SAMHD1 were counteracted in
MDMs and resting CD4+ T cells by adding dNs as dNTP precursors to
the culture medium 2 h before infection (Lahouassa et al., 2012;
Baldauf et al., 2012). Overall, this procedure did not affect the transduc-
tion rate of HSPCs (Figs. 2E and S1).Moreover, combining Vpx+viruses
and dNTPs had no effect on the transduction efﬁciency of HSPCs (data
now shown).
3.3. Vpx+virus pretreatments do not result in an accumulation of integrated
provirus and viral DNA intermediates in HSPCs
AGFP-based readout does not deﬁne at which level a potential block
exists in the HIV replication cycle, or may be even misleading when
studying restriction factors acting at various levels of theHIV replication
cycle. To address this issue, we ﬁrst quantiﬁed the integrated provirus
3 days post-infection by Alu-PCR. We found that Vpx signiﬁcantly
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enhanced HIV-1-based lentiviral vector integration in MDMs by more
than 15-fold over the Vpx− virus-treated controls; however, there
was nopositive effect of Vpx+viruses inHSPCs (Fig. 3A).Wewondered
whether Vpx might have an effect on earlier steps of the replication
cycle. However, this was not the case in HSPCs when examining early,
intermediate, or late transcripts (Fig. 3B).
3.4. HSPCs pretreated with Vpx+ viruses have lower amounts of SAMHD1
protein than mock-treated control
Wewondered whether the absence of effect of Vpx on transduction
efﬁcacy in HSPCs is due to a lack of its effect on SAMHD1 degradation.
We, thus, pretreated freshly isolated HSPCs from three donors with
Vpx+ viruses for 2 h, kept them for 3 days in a transduction medium,
and eventually harvested them for immunoblotting of SAMHD1. The
protein levels of SAMHD1 were comparable in cultured HSPCs and
MDMs; Vpx degraded SAMHD1 in HSPCs, but the absolute Vpx-
mediated decreases were signiﬁcantly lower in HSPCs than in MDMs
(Fig. 4A and B). Thus, the remaining SAMHD1 levels in HSPCs might
be sufﬁcient to block transduction. It also appears that HSPCs have
higher levels of p-SAMHD1 protein than MDMs subsequent to treat-
ment with Vpx+ viruses (Fig. 4C and D), pointing to a more efﬁcient
Vpx-dependent degradation of p-SAMHD1 in MDMs. It has to be
noted that the efﬁciency of Vpx+ viruses to degrade SAMHD1 in
MDMs is also donor dependent (Fig. 4A and C). Irrespective whether
the phosphorylated or unphosphorylated form of SAMHD1 is anti-HIV
active, we speculated that the degradation pathway is saturated with
the residual SAMHD1 in HSPCs.
3.5. Vpx viruses, dN and dNTP-pretreatment inﬂuence the intracellular
dNTP pools in HSPCs
The intracellular dNTP concentrations of HSPCs and whether they
will be affected by SAMHD1 are unknown. Thus, we determined the in-
tracellular dNTP levels in HSPCs at baseline and subsequent to treat-
ment with Vpx+/− viruses from three independent donors in a
single nucleotide incorporation assay 3 days later. dNTP concentrations
in both Vpx+ virus-pretreated HSPCs and MDMs were greater than in
Fig. 1. Characterization of HSPCs and GFP expression in lentiviral-transduced HSPCs by ﬂow cytometry and analysis of SAMHD1 expression in cultured HSPCs. (A) Freshly isolated cord
blood-derived HSPCs were cultured in the presence of cytokines as mentioned in “Materials and methods” section, and characterized by the cell surface expression of lineage markers,
CD34, CD133, CD38 over time. A representative dataset of three independent experiments is shown. Expression levels of mRNA (B) and protein of SAMHD1 (C and D) and p-SAMHD1
(E) were measured in freshly isolated HSPCs, HSPCs cultured for 3 days (B and C), 0–12 h (D) or 2–24 h (E) in a cytokine-enriched milieu, as well as in freshly isolated monocytes and
MDMs (C). THP-1 cells and Jurkat cells served as positive and negative controls, respectively, for Western blotting (C). RNA was extracted from 1 × 106 cells, cDNA was synthesized,
and the levels of SAMHD1 expression were analyzed by RT-qPCR. Data are presented as absolute copy numbers/100 ng of mRNA (n = 3). Dots represent individual measurements
withmean±SEM indicated. Statistical analysiswas doneusing two-tailed unpaired t-test. Protein levels of SAMHD1 andp-SAMHD1were determined byWestern blotting;β-actin served
as loading control. A representative dataset of three independent experiments is shown.
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Vpx− virus-treated cells (Fig. 5A and B). Cellular dNTP concentrations
were signiﬁcantly different in HSPCs and MDMs. HSPCs had 10–30
times lower dNTP concentrations than MDMs before and after Vpx+
virus treatment. Similarly, we evaluated whether adding dNs or dNTPs
changed the intracellular dNTP pool in HSPCs and MDMs. Indeed, it
did so in both cell types and there was amore prominent increase in in-
tracellular dNTP concentrations in dN-treated MDMs than in HSPCs
(Fig. 5C–F). The increase in dNTPs might still be insufﬁcient to support
efﬁcient reverse transcription, suggesting that low dNTPs could be a
restricting factor in cultured HSPCs.
3.6. Assessment of Vpx-mediated degradation of SAMHD1 when using a
lentivirus carrying Vpx+ and encoding GFP
To corroborate our data, we used shRNA to silence the expression
of SAMHD1. shRNA against SAMHD1 knocked down SAMHD1
Fig. 2. Vpx+ virus pretreatment has no effect on transduction efﬁciency. (A) Freshly isolated cord blood-derived HSPCs were cultured in the presence of cytokines as mentioned in Ma-
terials and methods section, HSPCs were challenged with Len-EF1α-GFP at an MOI of 100. Transduction efﬁciency was determined by quantifying the percentage of GFP+ HSPCs by ﬂow
cytometry. A representative dataset of three independent experiments is shown. HSPCs (B) orMDMs (C andD)were pretreated for 2 hwith Vpx+/− viruses. In (E), HSPCswere exposed
to 0.01 mM dNTPs. Transduction was performed with Len-EF1α-GFP at MOIs of 1, 10 and 100. Transduction efﬁciency was determined by quantifying the percentage of GFP+ HSPCs by
ﬂow cytometry (B and E) and by immunohistochemistry (C and D). Data are from three independent donors of MDMs and HSPCs. Dots represent three individual measurements with
mean ± SEM indicated. Statistical analysis used the two-tailed paired t-test.
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expression in THP-1 cells (Fig. S2A). It was less efﬁcient in HSPCs and
led only to a partial knockdown of SAMHD1, which did not translate
into any increase in the transduction rate (Fig. S2B). We saw no
difference, either when SAMHD1 shRNA and Vpx+ viruses were
combined. We cannot exclude that the lack of an increase in
transduction is due to the rather modest silencing or that viruses
Fig. 3.Vpx+virus treatment doesnot increase theproviralDNAor the viral DNA intermediates inHSPCs.MDMs andHSPCswere pretreated for 2 hwith Vpx+/− viruses, followedby Len-
EF1α-GFP transduction at anMOI of 100, and subsequently cultured for 3 days before harvesting. Data are presented as fold increase of samples pretreatedwith Vpx+ and Vpx− viruses
(A). MDMs or HSPCs transduced with HR-GFP-Vpx+ (HR-GFP-Vpx+ carries Vpx within the virions and its lentiviral gene encodes GFP) or HR-GFP-Vpx− at an MOI of 100, and subse-
quently cultured for 3 days before harvesting. Fold inductions of early, intermediate and late transcripts fromHR-GFP-Vpx+were determined by the ratio ofMNEs of samples exposed to
HR-GFP-Vpx+ and HR-GFP-Vpx−. (B). The dashed line indicates fold increase of 1. Quantiﬁcation of proviral DNA and viral DNA intermediates were done as described in “Materials and
methods” section. Dots represent three individual measurements with mean ± SEM indicated.
Fig. 4.Vpx+ virus treatmentmore effectively reduces SAMHD1 and p-SAMHD1 inMDMs than HSPCs. MDMs from nine donors andHSPCs from three donorswere pretreated for 2 hwith
Vpx+/− viruses before cell lysis. Protein levels of SAMHD1 and p-SAMHD1 were determined by Western blotting; β-actin served as loading control. A representative Western blot is
shown in (A and C) and semi-quantitative analysis of experiments is shown in (B and D). Dots represent individual measurements with mean ± SEM indicated in (B and D). Statistical
analysis was done using two-tailed paired t-test when comparing the same cell types from the same donor and unpaired one for comparison of distinct cell types (*P value if we use a
one sided test).
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containing Vpx may enter only a fraction of cells, which are not nec-
essarily targeted by subsequent viral challenge. In the latter case, we
may miss a Vpx-mediated effect on lentiviral transduction. Thus, we
eventually used a replication-incompetent HIV-1 GFP reporter virus
HR-GFP-Vpx+/−, which carries Vpx and encodes GFP, and its
control lacking Vpx (HR-GFP-Vpx−). Cells transduced by these
virions can be identiﬁed by GFP expression, and should be exposed
to Vpx's effects. In one representative example, SAMHD1 was
depleted from 4.96% in the mock-transduced to 1.9% in the HR-
GFP-Vpx+-transduced group 3 days after challenge, and depletion
lasted till day 7. Of note, GFP+ cells were detected mostly in the
cell population expressing low levels of SAMHD1 (Fig. 6A and B).
GFP+ cells were increased from 1.3% to 4.2% at day 7 compared
with HR-GFP-Vpx-transduced control (Fig. 6A). The number of
GFP+ cells and mean ﬂuorescence intensity (MFI) of GFP+ cells in
HR-GFP-Vpx+ transduced group increased signiﬁcantly more than
in the HR-GFP-Vpx− control (Fig. 6C and D), with the increase
being most prominent 7 days post-transduction. The residual cell
population expressing high amounts of SAMHD1 remained refracto-
ry to lentiviral transduction.
We observed a difference in transduction efﬁcacywhen Vpxwas de-
livered in trans or in cis. The decrease of SAMHD1 was similar with ei-
ther virus particle generated (Fig. 7). In fact, the similar decrease in
SAMHD1 excludes those of the Vpx-mediated effects observed with
the vector system in cis is only due to an overall more potent reduction
in SAMHD1; we hold on to our hypothesis that the consecutive chal-
lenge with virus particles which ﬁrst deliver Vpx in trans and second
the reporter gene, may target different cells and thus is poorly sensitive.
In contrast, the vector system in cis permits to focus on the very small
subsets of cells transduced.
4. Discussion
In the current study, we examined the role of SAMHD1 in restricting
HIV-1-based lentiviral transduction of HSPCs. We made several main
ﬁndings: i) SAMHD1 was highly expressed in HSPCs cultured with cyto-
kines. In contrast, freshly isolated HSPCs had low SAMHD1 expression.
Expression levels of SAMHD1 in cultured HSPCs were even close to
those found in myeloid cells, including monocytes and MDMs. ii) While
pretreatment of HSPCs with Vpx+ viruses or SAMHD1 shRNA resulted
in a signiﬁcant decrease of SAMHD1, we did not observe any increase in
subsequent lentiviral transduction. However, by using viruses carrying
Vpx and encoding GFP, which is more accurate for examining the role
of SAMHD1 in lentiviral transduction of HSPCs than the consecutive ex-
posure to viruses carrying Vpx and then viruses encoding GFP, we
found a signiﬁcant but modest increase in the number of GFP+ cells in
theHSPCs exposed to viruseswith Vpx. TheGFP+ cells exposed to viruses
carrying Vpx showed a decrease in SAMHD1 expression, pointing to Vpx-
mediated degradation of SAMHD1 resulting in the increased expression
of GFP. Thus, we concluded that Vpx promotes lentiviral-based transduc-
tion also in a subset of HSPCs but that other blocksmainly at cell entry are
the major limiting step for lentiviral-based transduction of HSPCs.
SAMHD1 emerges as a ubiquitous and potent barrier to productive
HIV-1 infection in DCs, myeloid cells, and resting CD4+ T cells. Thus, it
appeared likely that SAMHD1might also be effective when transducing
HSPCs with lentiviral vectors. Efﬁcient transduction of HSPCs requires
prestimulation with cytokines. We were surprised to ﬁnd that
SAMHD1 levels were very low or even absent in freshly isolated
HSPCs, while SAMHD1 was already highly expressed in HSPCs 2 h
after the start of culturing. Therefore, we hypothesized that Vpx-
mediated SAMHD1 degradation would result in a signiﬁcant increase
Fig. 5. Vpx+ virus, dN and dNTP treatments result in minor increases in the dNTP pool of HSPCs. MDMs (A, C and E) and freshly isolated HSPCs (B, D and F) were pretreated for 2 h with
Vpx+/− viruses, dNs or dNTPs, and cultured for 3 days before cell lysis. Quantiﬁcation of dNTPswas done by a single nucleotide incorporation assay (see “Material andmethods” section).
Fold induction was calculated based on the absolute values of vero- vs mock-treated samples (C–F). White dots represent Vpx− virus-pretreated samples, black dots represent Vpx+
virus-pretreated samples (A–B). White bars represent dN-pretreated samples, black bars represent dNTP-pretreated samples (C–F). Data are from three donors and bars represent
mean ± SEM. Statistical analysis was done using two-tailed paired t-test.
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in the transduction rate of HSPCs with lentiviral vectors. Surprisingly,
this was not the case. We even tested MOIs of 1 and 10 to exclude
that the conventionally used high MOI of 100 masked the effects of
Vpx+ VLP pretreatment (data not shown). To validate the results we
obtained bymonitoring GFP expression, we also quantiﬁed the number
of chromosomally integrated proviral DNA: resultswere identicalwith a
lack of increase of proviral DNA in HSPCs, while there was a substantial
increase inMDMs after pretreatmentwith Vpx+viruses.We also quan-
tiﬁed the viral DNA intermediates during reverse transcription in HSPCs
andMDMs pretreatedwith Vpx.We observed no increase in HSPCs and
a vigorous one inMDMs. Thus, overall, Vpx+viruses seemed to have no
role in relieving the block in lentiviral transduction in HSPCs.
We wondered if Vpx+ viruses participate in the degradation of
SAMHD1 in HSPCs. Indeed, that was the case: Vpx degraded SAMHD1
Fig. 6. Vpx partially overcomes restriction to HIV-1-based lentiviral transduction in HSPCs. HSPCswere transducedwith HR-GFP-Vpx+ or HR-GFP-Vpx− at anMOI of 100, andwere sub-
sequently cultured for 7 days. SAMHD1 and GFP expressions were analyzed by ﬂow cytometry at days 3 and 7 (A). The percentage of SAMHD1−GFP+ cells in total GFP+ cells is shown in
(B). MFI and transduction efﬁciency of HR-GFP-Vpx+ or HR-GFP-Vpx− transduced HSPCs are shown in (C and D). A representative dataset of three independent experiments is shown.
Statistical analysis was done using two-tailed paired t-test.
Fig. 7.HR-GFP-Vpx+/− and Vpx+/− viruses have similar efﬁcacy in degrading SAMHD1 in bothMDMs andHSPCs. MDMs andHSPCs from three donorswere transducedwith Vpx+/−
viruses orwithHR-GFP-Vpx+/− viruses before cell lysis. Protein levels of SAMHD1were determinedbyWesternblotting;β-actin served as loading control. A representativeWesternblot
is shown (A and B).
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in HSPCs, but residual levels tended to be higher in HSPCs than in
MDMs. Considering the data so far, we expected that Vpx had a more
modest effect in HSPCs than MDMs and thus a one-sided statistical
test can be justiﬁed; using a two-sided statistical test gave no signiﬁcant
result and thus we prefer to deﬁne it more as a trend than as a signiﬁ-
cant difference. We further veriﬁed to what extent Vpx affected the ac-
tivity of SAMHD1 or p-SAMHD1. p-SAMHD1 has no anti-HIV activity
while still being able to deplete the dNTP pool (White et al., 2013;
Cribier et al., 2013). Indeed, phosphorylation of SAMHD1 negatively
regulates SAMHD1's RNase activity and impedes HIV-1 restriction
(Ryoo et al., 2014). Taking into account our data so far, wewere not sur-
prised that HSPCs had a much higher p-SAMHD1 protein expression
than MDMs, and that Vpx had only a minor effect on decreasing p-
SAMHD1 in HSPCs. These results might explain that despite the overall
substantial Vpx-mediated decrease of SAMHD1 inHSPCs,we did not ob-
serve any clear change in the transduction rate.
While the mechanism of SAMHD1's anti-HIV activity (i.e., dNTPase
activity vs RNase activity) is controversial, we investigated whether
Vpx-mediated degradation of SAMHD1 affects the dNTP pool in
HSPCs. Vpx-mediated degradation of SAMHD1 only slightly increased
the dNTP pool in HSPCs, but greatly in MDMs, as reported (Lahouassa
et al., 2012). This negative result might be explained by the lack of deg-
radation of p-SAMHD1. We observed substantial increases of the dNTP
pools when adding dNs and less prominent ones when adding dNTPs
to the two cell types; again, it was much more pronounced in MDMs.
Lentiviral reverse transcriptases uniquely remain functional even at
the low dNTP concentrations found in non-dividing cells (Amie et al.,
2013). Thus, the regulation of the dNTP pools by SAMHD1 may be an
epiphenomenon of studying SAMHD1's anti-HIV activity rather than
being causally related. However, we cannot exclude that changes in
the dNTP pool may contribute to a minor extent to the reverse tran-
scriptase activity.
The assays used abovemight confound aminor role of Vpx-mediated
degradation of SAMHD1 since the consecutive treatment ﬁrst with virus-
es carrying Vpx or silencing SAMHD1with shRNA and the adding report-
er virusesmay not necessarily target the same cells. In contrast, this is the
case when using viruses carrying Vpx and encoding GFP, and thus, these
viruses may even reveal minor effects of Vpx on lentiviral transduction
rate (Lahouassa et al., 2012; Baldauf et al., 2012). Indeed, by this ap-
proach, we found a minor but signiﬁcant increase of GFP+ cells going
alongwith a decrease in SAMHD1.Moreover, the residual cell population
that expresses high amounts of SAMHD1 remained refractory to lentiviral
transduction.
From an evolutionary perspective, the high level of resistance of
HSPCs to lentiviruses makes sense, since any major chromosomal vul-
nerability would have more serious implications than in progeny cells.
The high-level expression of SAMHD1 in cultured HSPCs is reminiscent
of the one in activated CD4+ T cells (Baldauf et al., 2012). In activated
CD4+ T cells, the high expression of SAMHD1 goes along with a high
concentration of dNTP and high degree of permissiveness to HIV and
HIV-1-based transduction. In HSPCs, we encounter an entirely different
situation with a low concentration of dNTPs and a low permissiveness
to HIV-1-based lentiviral vectors. Thus, each cellular settingmust be ex-
amined separately.
5. Conclusions
In summary, HSPCs, in culture, express high levels of SAMHD1. Vpx-
mediated decrease of SAMHD1 relieves only marginally the restriction
of lentiviral-based transduction. The data imply that other blocks main-
ly at cell entry are the major limiting step for efﬁcient transduction. In-
deed, a recent study showed that the LDL receptor acts as the receptor
for VSV-G-pseudotyped particles (Amirache et al., 2014), and lack of it
appears to be at the origin of the poor permissiveness of HSPCs to
lentiviral transduction.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.06.012.
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